» Authors » Rhoda E Kuc

Rhoda E Kuc

Explore the profile of Rhoda E Kuc including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 59
Citations 1081
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Williams T, Verdon G, Kuc R, Currinn H, Bender B, Solcan N, et al.
Nat Commun . 2024 Dec; 15(1):10714. PMID: 39730334
We describe a structural and functional study of the G protein-coupled apelin receptor, which binds two endogenous peptide ligands, apelin and Elabela/Toddler (ELA), to regulate cardiovascular development and function. Characterisation...
2.
Owen N, Williams T, Maguire J, Kuc R, Davenport E, Davenport A
Biosci Rep . 2024 Jun; 44(7). PMID: 38860875
High blood pressure in the portal vein, portal hypertension (PH), is the final common pathway in liver cirrhosis regardless of aetiology. Complications from PH are the major cause of morbidity...
3.
Williams T, Nwokoye P, Kuc R, Smith K, Paterson A, Allinson K, et al.
Front Neurosci . 2024 May; 18:1379658. PMID: 38803685
Glioblastoma multiforme (GBM) is one of the most common and lethal forms of brain cancer, carrying a very poor prognosis (median survival of ~15 months post-diagnosis). Treatment typically involves invasive...
4.
Williams T, Kuc R, Paterson A, Abraham G, Pullinger A, Maguire J, et al.
Biosci Rep . 2024 May; 44(6). PMID: 38747277
Methods: Immunocytochemistry localised SGLT-2, ETA and ETB receptors in sections of histologically normal kidney, left ventricle from patients undergoing heart transplantation or controls. Primary antisera were visualised using fluorescent microscopy....
5.
Williams T, Nyimanu D, Kuc R, Foster R, Glen R, Maguire J, et al.
Front Pharmacol . 2024 Apr; 15:1369489. PMID: 38655187
Pulmonary arterial hypertension (PAH) is characterised by endothelial dysfunction and pathological vascular remodelling, resulting in the occlusion of pulmonary arteries and arterioles, right ventricular hypertrophy, and eventually fatal heart failure....
6.
Williams T, Macrae R, Kuc R, Brown A, Maguire J, Davenport A
Front Endocrinol (Lausanne) . 2023 Mar; 14:1139121. PMID: 36967803
Introduction: The apelin receptor binds two distinct endogenous peptides, apelin and ELA, which act in an autocrine/paracrine manner to regulate the human cardiovascular system. As a class A GPCR, targeting...
7.
Brevini T, Maes M, Webb G, John B, Fuchs C, Buescher G, et al.
Nature . 2022 Dec; 615(7950):134-142. PMID: 36470304
Preventing SARS-CoV-2 infection by modulating viral host receptors, such as angiotensin-converting enzyme 2 (ACE2), could represent a new chemoprophylactic approach for COVID-19 that complements vaccination. However, the mechanisms that control...
8.
Abraham G, Nyimanu D, Kuc R, Maguire J, Davenport A, Hoole S
J Interv Cardiol . 2022 Oct; 2022:9154048. PMID: 36262459
Objective: Coronary microvascular dysfunction (CMD) can complicate successful percutaneous coronary intervention (PCI). The potent endogenous vasoconstrictor peptide Endothelin-1 (ET-1) may be an important mediator. To investigate the mechanism, we sought...
9.
Macrae R, Colzani M, Williams T, Bayraktar S, Kuc R, Pullinger A, et al.
Cardiovasc Res . 2022 Oct; 119(2):587-598. PMID: 36239923
Aims: The apelin receptor, a G protein-coupled receptor, has emerged as a key regulator of cardiovascular development, physiology, and disease. However, there is a lack of suitable human in vitro...
10.
Nyimanu D, Chapman F, Gallacher P, Kuc R, Williams T, Newby D, et al.
Br J Clin Pharmacol . 2022 Jun; 88(12):5295-5306. PMID: 35748053
Aims: Chronic kidney disease (CKD) is common and cardiovascular disease (CVD) is its commonest complication. The apelin system is a potential therapeutic target for CVD but data relating to apelin...